EP1959943A1 - Antibiotiques s'administrant par voie orale destinés à traiter les douleurs hémorroïdaires - Google Patents
Antibiotiques s'administrant par voie orale destinés à traiter les douleurs hémorroïdairesInfo
- Publication number
- EP1959943A1 EP1959943A1 EP06818982A EP06818982A EP1959943A1 EP 1959943 A1 EP1959943 A1 EP 1959943A1 EP 06818982 A EP06818982 A EP 06818982A EP 06818982 A EP06818982 A EP 06818982A EP 1959943 A1 EP1959943 A1 EP 1959943A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibiotic
- use according
- group
- antibacterial
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000014617 hemorrhoid Diseases 0.000 title claims abstract description 19
- 239000003242 anti bacterial agent Substances 0.000 title claims description 13
- 229940088710 antibiotic agent Drugs 0.000 title description 12
- 230000003115 biocidal effect Effects 0.000 claims abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- 230000004260 plant-type cell wall biogenesis Effects 0.000 claims description 4
- 238000001243 protein synthesis Methods 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 230000014616 translation Effects 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 229940127249 oral antibiotic Drugs 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 239000004187 Spiramycin Substances 0.000 claims description 2
- 108010034396 Streptogramins Proteins 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960003306 fleroxacin Drugs 0.000 claims description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940124307 fluoroquinolone Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 239000002271 gyrase inhibitor Substances 0.000 claims description 2
- 229940041028 lincosamides Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229960001180 norfloxacin Drugs 0.000 claims description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 150000007660 quinolones Chemical class 0.000 claims description 2
- 229960001294 spiramycin Drugs 0.000 claims description 2
- 235000019372 spiramycin Nutrition 0.000 claims description 2
- 229930191512 spiramycin Natural products 0.000 claims description 2
- 229940041030 streptogramins Drugs 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 229940040944 tetracyclines Drugs 0.000 claims description 2
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- -1 sulfadiacin Chemical class 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 2
- 229960001082 trimethoprim Drugs 0.000 claims 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims 1
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 claims 1
- 229950001320 clinafloxacin Drugs 0.000 claims 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- 229940041009 monobactams Drugs 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960004918 nimorazole Drugs 0.000 claims 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 claims 1
- 150000004957 nitroimidazoles Chemical class 0.000 claims 1
- 229960004954 sparfloxacin Drugs 0.000 claims 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 1
- 229960005053 tinidazole Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000015815 Rectal disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- 206010049555 Anal haemorrhage Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000549173 Celastrus scandens Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021071 low fiber diet Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000001990 thiamine group Chemical group 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the use of an oral antibiotic.
- Antibiotics are drugs that are used to treat infectious diseases.
- the scope of the antibiotics extends to
- bacterial infectious diseases e.g. cholera, diphtheria, gonorrhea, whooping cough, leprosy, scarlet fever, syphilis, tuberculosis, typhoid and
- - mycoses e.g. aspergillosis, dermatophytosis and candidiasis
- - Protozoan diseases e.g. malaria, Pneumocystis carinii pneumonia, toxoplasmosis
- - Virus diseases e.g. measles, rubella, herpes simplex and zoster, real flu and flu infections, poliomyelititis and HIV infections).
- Anorectal diseases such as hemorrhoids in particular, are bothersome and accompanied by malaise.
- Hemorrhoids are battle-like dilations of the veins in the transition from the rectum to the rectum. Chronic constipation, which is often caused by wrong eating habits with a low-fiber diet, is considered the main cause. A lack of hydration, sedentary activity, being overweight and too little exercise additionally support this intestinal sluggishness. Often there is also a connective tissue weakness with a simultaneous tendency to varicose veins. Hemorrhoids are a common condition in the anorectal area and can occur both internally and externally. Anorectal complaints are characterized by the symptoms of itching, Burning, pain, bleeding, leprosy, inflammation, irritation and increase in general discomfort and a change in bowel movements or a combination of these symptoms.
- Anorectal disorders are very common in humans. No one is immune. The majority of adults suffer from one or more anorectal symptoms at some point in their life cycle. Anorectal complaints have resulted in an uncountable number of hours lost in the workplace.
- DE 200 19 116 U1 proposes a cooling compress for the swelling of outer hemorrhoids, which has an anatomically adaptable outer skin, is filled with cooling mass and the outer skin covering of which is suitable for taking decongestant medication.
- surgical interventions also occur, with the ligature being mentioned due to the high ligature.
- DE 35 27 762 also shows a surgical device for setting hemorrhoids.
- DE 38 56 018 T2 proposes a disaccharide-polysulfate-aluminum compound for the manufacture of a medicament for the treatment of hemorrhoids and for wound healing.
- US 4,613,498 describes a powder mixture of aluminum, quinine sulfate and aspirin, which is mixed with petroleum mass.
- a Mixture of oxidase enzymes is described in US RE 28,011.
- a description of a mixture of root parts of the bush Celastrus scandens present in powder or bar form is given in US 3,935,310.
- EP 0 035 058 A1 finally describes a composition of thiamine, riboflavin, pyridoxine, cobalamin, niazine amide and pantothenic acid in liquid form for oral use.
- the object of the present invention is to expand the area of use of the antibiotics.
- the solution to the problem is the use of an oral antibiotic to combat hemorrhoids.
- hemorrhoids Similar to the recently discovered bacterial genesis of gastric and duodenal ulcer disease, which was formerly considered to be classic psychosomatic, hemorrhoidal disease could also be a special colonization of the rectum with certain harmful bacteria caused by treatment with antibiotics be eliminated. In this case, the elimination of these bacteria would be the goal of oral antibiosis.
- antibacterial antibiotics are preferred.
- antibacterial drugs with an attack on cell wall synthesis antibacterial inhibitors of protein synthesis and antibacterial drugs with an effect on nucleic acid should be used.
- antibiotics are selected from the group of ⁇ -lactam antibiotics and here in particular the penicillins, cephalosporins, carbacephemes and monobaktams.
- the group of antibiotics with antibacterial inhibitors of protein synthesis is extensive. These include above all the group of aminoglycosides and in particular the streptomycin, neomycin, kanamycin-gentamicin group.
- the group of tetracyclines deserves special mention here, in particular doxycycline and minocylin.
- the inventor treated about 20 patients suffering from hemorrhoids with doxycycline. As early as 48 hours after the start of oral administration, the cardinal symptoms of pain, itching, and anal bleeding had abated considerably. In the further course, usually within 7 to 14 days, the mechanically very painful enlarged veins, which maintain the disease as the main pathological anatomical detail, largely regressed.
- Antibiotics from the macrolide group are also conceivable, and here in particular erytromycin, clarithromycin, roxitromycin and spiramycin. From the group of lincosamides, clindamycin should be mentioned in particular.
- the antibiotics can also be selected from the group of fusic acids, oxazolidinones and streptogramins.
- the group of fluoroquinolones and analogs (gyrase inhibitors) should be mentioned in particular of the antibacterially active pharmaceuticals which act on nucleic acid. These include the antibiotic of the norfloxacin type and those from the group of standard quinolones, in particular ciprofloxacin, fleroxacin, ofloxacin and lefloxacin.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une utilisation d'un antibiotique s'administrant par voie orale pour calmer les douleurs hémorroïdaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005058345A DE102005058345A1 (de) | 2005-12-06 | 2005-12-06 | Verwendung eines oral einzunehmenden Antibiotikums |
| PCT/EP2006/011671 WO2007065637A1 (fr) | 2005-12-06 | 2006-12-05 | Antibiotiques s'administrant par voie orale destinés à traiter les douleurs hémorroïdaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1959943A1 true EP1959943A1 (fr) | 2008-08-27 |
Family
ID=37808349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06818982A Ceased EP1959943A1 (fr) | 2005-12-06 | 2006-12-05 | Antibiotiques s'administrant par voie orale destinés à traiter les douleurs hémorroïdaires |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1959943A1 (fr) |
| DE (1) | DE102005058345A1 (fr) |
| WO (1) | WO2007065637A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497053B (zh) | 2015-12-31 | 2018-02-13 | 沈阳福洋医药科技有限公司 | 可利霉素在抗结核分枝杆菌感染中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE28011E (en) | 1972-11-20 | 1974-05-14 | Pharmaceutical preparation | |
| US3935310A (en) | 1974-03-07 | 1976-01-27 | Homan John D | Remedy for treatment of hemorrhoids |
| US4265887A (en) | 1979-12-11 | 1981-05-05 | Breskman Joseph S | Composition and method for treatment of hemorrhoids |
| GB9822681D0 (en) | 1998-10-16 | 1998-12-09 | Vitabiotics Ltd | Method of treatment |
| CN100367982C (zh) | 2002-12-31 | 2008-02-13 | 何家厚 | 一种医治痔疮的软膏的生产方法 |
-
2005
- 2005-12-06 DE DE102005058345A patent/DE102005058345A1/de not_active Withdrawn
-
2006
- 2006-12-05 EP EP06818982A patent/EP1959943A1/fr not_active Ceased
- 2006-12-05 WO PCT/EP2006/011671 patent/WO2007065637A1/fr not_active Ceased
Non-Patent Citations (6)
| Title |
|---|
| "Pharmazeutischge Stoffliste Am-Az", 1 January 2010, pages: 139 - 154 * |
| "Rote Liste 1995", pages: 25 - 26 * |
| "Rote Liste 2005", article PAGE 74, 10 177, 10 178 * |
| "Wikipedia Doxycycline" * |
| ROBBINS M ET AL: "THE IN-VITRO ACTIVITY OF DOXYCYCLINE AND MINOCYCLINE AGAINST ANAEROBIC BACTERIA", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 20, no. 3, 1987, pages 379 - 382, XP009152379, ISSN: 0305-7453 * |
| See also references of WO2007065637A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE102005058345A1 (de) | 2007-06-14 |
| WO2007065637A1 (fr) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69328967T2 (de) | Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums | |
| DE69634171T2 (de) | Mikroverkapselte Kaktobacilli für medizinische Anwendungen | |
| DE3887353T2 (de) | Behandlungsverfahren für magen-darm-krankheiten. | |
| DE69831609T2 (de) | Pharmazeutische zusammensetzung zur stimulierung des wachstums von gram-positiven bazillen und zur erhöhung der azidität der vagina und ihre verwendung | |
| DE69133348T2 (de) | Behandlung von nicht-entzündlichen darmerkrankungen | |
| EP2099462B1 (fr) | Préparation pharmaceutique pour le traitement de pathologies inflammatoires du système urogénital | |
| CH660969A5 (de) | Verwendung von thiadiazinverbindungen. | |
| DE19737348C2 (de) | Neue Clindamycin und Clotrimazol enthaltende pharmazeutische Zusammensetzung | |
| CH659391A5 (de) | Koffein enthaltende, analgetische und antiinflammatorische pharmazeutische zubereitung. | |
| DE69707927T2 (de) | Verbesserungen bezüglich langwirksamer antibiotika | |
| DE2721785A1 (de) | Oral verabfolgbares cephalexinpraeparat mit verzoegerter wirkstoffabgabe | |
| ATTHEWS et al. | Dermographism: reduction in weal size by chlorpheniramine and hydroxyzine | |
| EP1959943A1 (fr) | Antibiotiques s'administrant par voie orale destinés à traiter les douleurs hémorroïdaires | |
| DE102020134587B4 (de) | 1,8-Cineol enthaltende Zusammensetzung für die therapeutische Verwendung | |
| CH662510A5 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel. | |
| DE1917283C3 (de) | Herstellung antimikrobieller Präparate | |
| Hersle | Trimethoprim-Sulphamethoxazole in Acne vulgaris A Double-Blind Study | |
| US20030207819A1 (en) | Compositions and methods for treating inflammatory connective tissue diseases | |
| RU2349339C1 (ru) | Средство, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, стимулирующим регенерацию хрящевой и соединительной ткани свойствами | |
| DE60124732T2 (de) | Gatifloxacin als inhibitor der cytokinproduktion | |
| Kato et al. | Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients | |
| DE69529981T2 (de) | Verwendung von spiramyeine in von h.pylori verursachten magen und darm beschwerden | |
| EP2120918B1 (fr) | Composition pharmaceutique pour le traitement de l'incontinence | |
| DE3785953T2 (de) | Bakterientötende Gemische. | |
| Mahdi et al. | Effects of chitosan and hyaluronic acid in healing of chemically induced oral ulcer in rabbits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080707 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20081230 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20120503 |